Category: Boston Scientific
Volcano and Boston Scientific use their respective devices simultaneously for more accurate stent placement in a new study announced at EuroPCR
Volcano Corporation (NSDQ:VOLC) and Boston Scientific (NYSE:BSX) announced a new, cosponsored Syntax study to test precision in stent placement.
The companies announced the upcoming study at the EuroPCR annual meeting in Paris, France.
Medical device giant Boston Scientific touts very low rates of paravalvular leakage in 30-day results from its Lotus transcatheter aortic valve implantation study.
Massachusetts-based medical device titan Boston Scientific (NYSE:BSX) released early data from a study of its Lotus transcatheter aortic valve implantation system, highlighting very low rates of paravalvular leakage that analysts said could give the company some leverage in the highly charged TAVI market.
Boston Scientific denies allegations by stents rival OrbusNeich that it tried to block the seizure of stants whose importation is banned in Germany.
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival Boston Scientific over cardiac rhythm management technology.
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is one of the most blatant plagiarisms of a patented medical device" he's ever encountered.
The European Union's 2nd-largest medical device market dips into recession during the 1st 3 months of 2013, meaning more bad news as Europe's economy continues to worsen.
Bad news out of the EuroZone this week as more of the top economies across the pond slipped into a recession, including the European Union's 2nd-largest market for medical devices.
Eurostat, the statistical office of the European Union, said yesterday that the gross domestic product of the 17-nation alliance contracted 0.2% during the first 3 months of 2013 compared to the previous quarter and 1% compared to the same period last year.
Boston Scientific's stock price breaks the $9 barrier today on the launch of a clinical trial of its WallFlex self-expanding biliary stent.
Boston Scientific (NYSE:BSX) shares hit a new 52-week high today after the medical device company announced the launch of a clinical trial of its WallFlex biliary stent.
